363 related articles for article (PubMed ID: 21881032)
1. Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia.
Tsu LV; Dager WE
Ann Pharmacother; 2011 Oct; 45(10):1185-92. PubMed ID: 21881032
[TBL] [Abstract][Full Text] [Related]
2. Correlation of bivalirudin dose with creatinine clearance during treatment of heparin-induced thrombocytopenia.
Runyan CL; Cabral KP; Riker RR; Redding D; May T; Seder DB; Savic M; Hedlund J; Abramson S; Fraser GL
Pharmacotherapy; 2011 Sep; 31(9):850-6. PubMed ID: 21923585
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia.
Kiser TH; Burch JC; Klem PM; Hassell KL
Pharmacotherapy; 2008 Sep; 28(9):1115-24. PubMed ID: 18752382
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction.
Kiser TH; Fish DN
Pharmacotherapy; 2006 Apr; 26(4):452-60. PubMed ID: 16553502
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bivalirudin dosing strategies using total, adjusted, and ideal body weights in obese patients with heparin-induced thrombocytopenia.
Tsu LV; Dager WE
Pharmacotherapy; 2012 Jan; 32(1):20-6. PubMed ID: 22392825
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study.
Orzel LA; Abel EE; Blais DM; Wang TF; Porter KA; Burcham PK
Pharmacotherapy; 2019 Dec; 39(12):1157-1166. PubMed ID: 31587337
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
[TBL] [Abstract][Full Text] [Related]
8. Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia.
Al-Ali FS; Elsayed M; Khalifa S; Abdulla AE; Tolba H; Bouanane H; Ibrahim R; Hamad A
Hemodial Int; 2016 Apr; 20(2):204-7. PubMed ID: 26501237
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bivalirudin to lepirudin and argatroban in patients with heparin-induced thrombocytopenia.
Bain J; Meyer A
Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S104-9. PubMed ID: 26272889
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia.
Wisler JW; Washam JB; Becker RC
J Thromb Thrombolysis; 2012 Apr; 33(3):287-95. PubMed ID: 22271374
[TBL] [Abstract][Full Text] [Related]
11. Development and implementation of a nurse-driven, sliding-scale nomogram for bivalirudin in the management of heparin-induced thrombocytopenia.
Burcham PK; Abel EE; Gerlach AT; Murphy CV; Belcher M; Blais DM
Am J Health Syst Pharm; 2013 Jun; 70(11):980-7. PubMed ID: 23686604
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Dang CH; Durkalski VL; Nappi JM
Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study.
Pieri M; Agracheva N; Bonaveglio E; Greco T; De Bonis M; Covello RD; Zangrillo A; Pappalardo F
J Cardiothorac Vasc Anesth; 2013 Feb; 27(1):30-4. PubMed ID: 23036625
[TBL] [Abstract][Full Text] [Related]
14. [Optimal dose of bivalirudin in dialysis patients at high risk of heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case report].
Notarangelo MF; Coppini L; Bontardelli F; Boffetti F; Vignali L; Ardissino D
G Ital Cardiol (Rome); 2013 Feb; 14(2):141-4. PubMed ID: 23389318
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Vo QA; Lin JK; Tong LM
Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
[TBL] [Abstract][Full Text] [Related]
16. Incidence of bleeding in renally impaired patients receiving incorrectly dosed eptifibatide or bivalirudin while undergoing percutaneous coronary intervention.
Taylor LA; Mauro VF
Ann Pharmacother; 2012 Jan; 46(1):35-41. PubMed ID: 22170973
[TBL] [Abstract][Full Text] [Related]
17. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.
Tschudi M; Lämmle B; Alberio L
Blood; 2009 Mar; 113(11):2402-9. PubMed ID: 19059879
[TBL] [Abstract][Full Text] [Related]
18. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
[TBL] [Abstract][Full Text] [Related]
19. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy.
Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Pharmacother; 2009 Jul; 43(7):1360-5. PubMed ID: 19584380
[TBL] [Abstract][Full Text] [Related]
20. Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy.
Kiser TH; MacLaren R; Fish DN; Hassell KL; Teitelbaum I
Pharmacotherapy; 2010 Nov; 30(11):1117-26. PubMed ID: 20973685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
